Lantern Pharma (Nasdaq: LTRN) reported a median progression-free survival of 8.3 months for LP-300 in 16 patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who had progressed on prior TKI therapy, with the upper confidence interval remaining uncalculated at the time of analysis — a finding the company is now using to justify proposed protocol amendments to its Phase II HARMONIC trial ahead of a scheduled Type C FDA meeting in mid-May 2026.
The HARMONIC trial (NCT05456256) is a Phase II study evaluating LP-300 in combination with carboplatin and pemetrexed in never-smokers with advanced NSCLC who have progressed on TKI therapy, enrolling patients across sites in the United States, Japan, and Taiwan.
Among the 16 L858R-mutant patients enrolled, the triplet regimen produced a median PFS of 8.3 months (95% CI: 6.2 to not calculable) and an objective response rate of 43%, with an 86% clinical benefit rate reported from the US safety lead-in cohort. A hazard ratio of 0.37 (95% CI: 0.15–0.89) was observed when comparing L858R to non-L858R patients, and that mutation-specific signal held after multivariable adjustment for race, gender, and TP53 status. The data carry significant limitations: the cohort is small, the analysis is exploratory, and the open upper confidence interval reflects the immature follow-up rather than confirmed long-term control.
Adverse events were limited. LP-300 added one treatment-related serious adverse event (3%) across 31 patients in the safety dataset, with rash in 7% and no paronychia — a profile the company contrasts with published MARIPOSA-2 data, where amivantamab plus chemotherapy produced treatment-related SAEs in 23% of patients, rash in 43%, and paronychia in 36%. Cross-trial comparisons are limited by differences in patient populations, study design, and data collection methodology, and should not be interpreted as direct evidence of comparative efficacy or safety.
LP-300 is a disulfide-active small molecule whose metabolites form covalent adducts with cysteine residues in the EGFR extracellular domain, with a proposed mechanism centered on disruption of receptor dimerization. This is mechanistically distinct from all approved EGFR inhibitors, which act at the intracellular ATP-binding pocket, and from amivantamab, which blocks extracellular ligand binding at both EGFR and MET. The biological rationale for L858R selectivity rests on the observation that, unlike Exon 19 deletion tumors — which can activate as monomers — L858R tumors retain a dependence on receptor dimerization for full oncogenic activation. Lantern acknowledges this remains a hypothesis requiring experimental validation and plans to incorporate mechanistic studies into the amended protocol. The most directly relevant approved comparator in the post-TKI setting is amivantamab plus carboplatin and pemetrexed (FDA-approved September 2024 based on MARIPOSA-2, which carries a meaningful toxicity burden driven by EGFR/MET antibody-related skin and infusion reactions. Whether LP-300's preliminary tolerability advantage translates into a clinically differentiated profile will require data from a larger, prospectively designed cohort.